SCHEMBL1439403

SCHEMBL1439403

CC(C)(C)OC(=O)Nc1cc(B(O)O)ccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
PDK1 Q15118 2/20 0.41
PDK2 Q15119 2/20 0.41
PDK3 Q15120 2/20 0.41
PDK4 Q16654 2/20 0.41
HIF1A Q16665 1/20 0.39
ATR Q13535 1/20 0.39
ALDH1A1 P00352 1/20 0.38
RXFP1 Q9HBX9 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
POLB P06746 1/20 0.36
P2RX7 Q99572 1/20 0.36
LCK P06239 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
NPC1 O15118 1/20 0.36
ALOX12 P18054 1/20 0.36
BRD9 Q9H8M2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3784938 0.87 HPGD (0.44) HIF1ARXFP1TRPV1BRD9
SCHEMBL29952945 0.84 LMNA (0.41) HIF1AALDH1A1RXFP1POLBTRPV1
SCHEMBL28738831 0.82 PDK1 (0.56) HSP90AA1HSP90AB1PDK1PDK2PDK3
SCHEMBL6856839 0.82 PDK1 (0.58) HSP90AA1HSP90AB1PDK1PDK2PDK3
SCHEMBL1676565 0.82 GAA (0.45) ALDH1A1MEN1KMT2APOLB
SCHEMBL21682754 0.81 SMN1; SMN2 (0.44) HIF1AALDH1A1RXFP1MEN1KMT2A
SCHEMBL3789950 0.81 CA12 (0.48) HSP90AA1HSP90AB1PDK1PDK2PDK3
SCHEMBL29956067 0.80 CYP17A1 (0.50) HIF1ARXFP1POLBTRPV1NPC1
SCHEMBL1256341 0.80 CYP17A1 (0.50) HIF1ARXFP1POLBTRPV1NPC1
SCHEMBL24874053 0.80 HIF1A (0.37) HSP90AA1HSP90AB1HIF1AALDH1A1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
WO-2012101064-A1 N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2012-08-02 WO disclosed
EP-2473502-A1 HETEROARYL COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2012-07-11 EP disclosed
US-20120157433-A1 Heteroaryl Compounds as Kinase Inhibitors PFISTER KEITH B (US) 2012-06-21 US disclosed
CN-102498107-A Heteroaryl compounds as kinase inhibitors NOVARTIS AG 2012-06-13 CN disclosed
WO-2012066065-A1 PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2012-05-24 WO disclosed
WO-2011026917-A1 HETEROARYL COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2011-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157433-A1 Heteroaryl Compounds as Kinase Inhibitors CDK2, CDK1, CDK6 HSP90AA1 2499/4885HSP90AB1 2024/4885PDK1 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.